Making the Most of Treatment Advances in SCLC: New Standards, Practicalities of Care, and Hope on the Horizon

1.50 hr(s) | CME , MOC , ABIM

Specialty: SCLC

Therapeutic Area(s): Oncology

Release Date: June 15, 2021

Expiration Date: June 15, 2021

Location: Live Webcast

Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and a unique myeloprotective agent has become available that can decrease the incidence of chemotherapy-induced myelosuppression in patients with SCLC. These developments have provided new hope to patients with SCLC, but they have also increased the urgency to diagnose and treat SCLC in a timely manner to ensure patients can derive benefits from these therapies.

Access this activity
Share via
Copy link
Powered by Social Snap